Designing Potent TCR-based T-Cell Engagers for Cancer Immunotherapy with Generative AI
- Applying our proprietary machine learning platform, EMLy, for TCR discovery leading and affinity enhancement, leading to the development of potent and safe TCR-based T-cell engagers
- Leveraging AI to optimise multi-specific modalities, to enhance immune activation and efficacy against solid tumours
- Integrating AI in the design phase to improve solubility, reduce aggregation, and boost protein yield, ensuring candidate molecules are both potent and manufacturable at scale